Review Article | Published:

Therapy Insight: bladder dysfunction associated with multiple sclerosis

Nature Clinical Practice Urologyvolume 2pages492501 (2005) | Download Citation

Subjects

Abstract

Bladder dysfunction is a common problem for patients with multiple sclerosis. The severity of symptoms often correlate with the degree of spinal cord involvement and, hence, the patient's general level of disability. The emphasis of management is now mainly medical and is increasingly offered by nonurologists. Treatments can be highly effective, relieving patients of what are otherwise very troublesome symptoms that would compound their neurological disability. This article gives an overview of the neural control of the bladder, followed by an explanation of the pathophysiology of detrusor overactivity secondary to neurological disease. A review of methods available for treating bladder dysfunction in multiple sclerosis then follows. The treatment options for this disorder are largely medical and include established first-line measures such as anticholinergics, clean intermittent self-catheterization and the use of desmopressin, as well as potential second-line agents, such as cannabinoids, intravesical vanilloids and intradetrusor botulinum neurotoxin type A. The diminishing role of surgical intervention is also discussed.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Litwiller SE et al. (1999) Multiple sclerosis and the urologist. J Urol 161: 743–757

  2. 2

    Betts CD et al. (1993) Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatry 56: 245–250

  3. 3

    Hawker KS and Frohman EM (2001) Bladder, Bowel, and Sexual Dysfunction in Multiple Sclerosis. Curr Treat Options Neurol 3: 207–214

  4. 4

    Miller H et al. (1965) Bladder Dysfunction in Multiple Sclerosis. Br Med J 5445: 1265–1269

  5. 5

    Kidd DJ et al. (1993) Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology 43: 2632–2637

  6. 6

    Zivadinov R et al. (2003) The use of standardized incidence and prevalence rates in epidemiological studies on multiple sclerosis. A meta-analysis study. Neuroepidemiology 22: 65–74

  7. 7

    Koldewijn EL et al. (1995) Relationship between lower urinary tract abnormalities and disease-related parameters in multiple sclerosis. J Urol 154: 169–173

  8. 8

    Nortvedt MW et al. (2001) Reduced quality of life among multiple sclerosis patients with sexual disturbance and bladder dysfunction. Mult Scler 7: 231–235

  9. 9

    Fernandez O (2002) Mechanisms and current treatments of urogenital dysfunction in multiple sclerosis J Neurol 249: 1–8

  10. 10

    Athwal BS et al. (2001) Brain responses to changes in bladder volume and urge to void in healthy men. Brain 124: 369–377

  11. 11

    Matsuura S et al. (2002) Human brain region response to distention or cold stimulation of the bladder: a positron emission tomography study. J Urol 168: 2035–2039

  12. 12

    Blok BF et al. (1997) A PET study on brain control of micturition in humans. Brain 120: 111–121

  13. 13

    Blok BF et al. (1998) Brain activation during micturition in women. Brain 121: 2033–2042

  14. 14

    Blok BF (2002) Central pathways controlling micturition and urinary continence. Urology 59 (Suppl 1): S13–S17

  15. 15

    Blaivas JG and Barbalias GA (1984) Detrusor-external sphincter dyssynergia in men with multiple sclerosis: an ominous urologic condition. J Urol 131: 91–94

  16. 16

    de Groat WC et al. (1990) Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J Auton Nerv Syst 30 (Suppl): S71–S77

  17. 17

    Birder L et al. (1998) Adrenergic- and capsaicin-evoked nitric oxide release from urothelium and afferent nerves in urinary bladder. Am J Physiol 275: F226–F229

  18. 18

    Andersson KE (2001) The basis for drug treatment of the overactive bladder. World J Urol 19: 294–298

  19. 19

    Abrams PL et al. (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61: 37–49

  20. 20

    Wheeler JS Jr et al. (1983) The changing neurourologic pattern of multiple sclerosis. J Urol 130: 1123–1126

  21. 21

    Ciancio SJ et al. (2001) Urodynamic pattern changes in multiple sclerosis. Urology 57: 239–245

  22. 22

    Awad SA et al. (1984) Relationship between neurological and urological status in patients with multiple sclerosis. J Urol 132: 499–502

  23. 23

    Lycklama A et al. (1998) Brain and Spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. Brain 121: 687–697

  24. 24

    Kim Y et al. (1998) The correlation of urodynamic findings with cranial magnetic resonance imaging findings in multiple sclerosis. J Urol 159: 972–976

  25. 25

    Ukkonen M et al. (2004) Urodynamic findings in primary progressive multiple sclerosis are associated with increased volumes of plaques and atrophy in the central nervous system. Acta Neurol Scand 109: 100–105

  26. 26

    Sirls LT et al. (1994) Role of limited evaluation and aggressive medical management in multiple sclerosis: a review of 113 patients. J Urol 151: 946–950

  27. 27

    Chess-Williams R et al. (2001) The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol 21: 243–248

  28. 28

    Sigala S et al. (2002) Differential gene expression of cholinergic muscarinic receptor subtypes in male and female normal human urinary bladder. Urology 60: 719–725

  29. 29

    Harriss DR et al. (1995) Expression of muscarinic M3-receptors coupled to inositol phospholipid hydrolysis in human detrusor cultured smooth muscle cells. J Urol 154: 1241–1245

  30. 30

    Clemett D and Jarvis B (2001) Tolterodine: a review of its use in the treatment of overactive bladder. Drugs Aging 18: 277–304

  31. 31

    Todorova A et al. (2001) Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 41: 636–644

  32. 32

    Kornhuber HH and Schutz A (1990) Efficient treatment of neurogenic bladder disorders in multiple sclerosis with initial intermittent catheterization and ultrasound-controlled training. Eur Neurol 30: 260–267

  33. 33

    Fowler CJ (1996) Investigation of the neurogenic bladder. J Neurol Neurosurg Psychiatry 60: 6–13

  34. 34

    Fowler CJ et al. (1992) Treatment of lower urinary tract dysfunction in patients with multiple sclerosis. Committee of the European Study Group of SUDIMS (Sexual and Urological Disorders in Multiple Sclerosis). J Neurol Neurosurg Psychiatry 55: 986–989

  35. 35

    Seland PT et al. (1999) Urinary dysfunction and Multiple Sclerosis. Evidence-Based Management Strategies for Urinary Dysfunction in Multiple Sclerosis. Multiple Sclerosis Council for Clinical Practice Guidelines. Washington DC: PVA Publications

  36. 36

    Kaplan SA et al. (1991) Bladder and sphincter behavior in patients with spinal cord lesions. J Urol 146: 113–117

  37. 37

    Barbalias GA et al. (1998) Vesicourethral dysfunction associated with multiple sclerosis: clinical and urodynamic perspectives. J Urol 160: 106–111

  38. 38

    Norlen L and Sundin T (1978) Alpha-adrenolytic treatment in patients with autonomous bladders. Acta Pharmacol Toxicol (Copenh) 43 (Suppl 2): S31–S34

  39. 39

    O'Riordan JI et al. (1995) Do alpha-blockers have a role in lower urinary tract dysfunction in multiple sclerosis? J Urol 153: 1114–1116

  40. 40

    Schwinn DA (2000) Novel role for alpha1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int 86 (Suppl 2): S11–S20

  41. 41

    Nathan P (1977) Emptying the paralysed bladder. Lancet 1: 377

  42. 42

    Dasgupta P et al. (1997) The 'Queen Square bladder stimulator': a device for assisting emptying of the neurogenic bladder. Br J Urol 80: 234–237

  43. 43

    Prasad RS et al. (2003) Lower abdominal pressure versus external bladder stimulation to aid bladder emptying in multiple sclerosis: a randomized controlled study. Clin Rehabil 17: 42–47

  44. 44

    Rew DA and Rundle JS (1989) Assessment of the safety of regular DDAVP therapy in primary nocturnal enuresis. Br J Urol 63: 352–353

  45. 45

    Hilton P et al. (1983) The use of desmopressin (DDAVP) for nocturia in women with multiple sclerosis. J Neurol Neurosurg Psychiatry 46: 854–855

  46. 46

    Hoverd PA and Fowler CJ (1998) Desmopressin in the treatment of daytime urinary frequency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 65: 778–780

  47. 47

    Tubridy N et al. (1999) Long term use of desmopressin for urinary symptoms in multiple sclerosis. Mult Scler 5: 416–417

  48. 48

    Gades NM et al. (2005) Prevelence of conditions potentially associated with lower urinary tract symptoms in men. BJU Int 95: 554–593

  49. 49

    AUA Practice Guidelines Committee (2003) AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 170: 530–547

  50. 50

    House of Lords Committee on Science and Technology (1998) House of Lords Committee on Science and Technology. Cannabis: the scientific and medical evidence (9th report). London: Stationary Office

  51. 51

    Brady CM et al. (2004) An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 10: 425–433

  52. 52

    Zajicek J et al. (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362: 1517–1526

  53. 53

    Freeman R et al. (2004) The effect of cannabinoids on lower urinary tract symptoms in multiple sclerosis: a randomised placebo controlled trial (CAMS-LUTS study). Neurourol Urodyn 23: 607 (A149)

  54. 54

    Fowler CJ et al. (1992) Intravesical capsaicin for neurogenic bladder dysfunction. Lancet 339: 1239

  55. 55

    de Seze M et al. (1999) Intravesical instillation of capsaicin in urology: A review of the literature. Eur Urol 36: 267–277

  56. 56

    Appendino G and Szallasi A (1997) Euphorbium: modern research on its active principle, resiniferatoxin, revives an ancient medicine. Life Sci 60: 681–696

  57. 57

    Giannantoni A et al. (2002) Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: a prospective randomized study. J Urol 167: 1710–1714

  58. 58

    Cruz F (2002) Vanilloid receptor and detrusor instability. Urology 59 (Suppl 1): S51–S60

  59. 59

    Brady CM et al. (2004) Parallel changes in bladder suburothelial vanilloid receptor TRPV1 (VR1) and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity (NDO) following intravesical resiniferatoxin treatment. BJU Int 93: 770–776

  60. 60

    de Seze M et al. (2004) Intravesical capsaicin versus resiniferatoxin for the treatment of detrusor hyperreflexia in spinal cord injured patients: a double-blind, randomized, controlled study. J Urol 171: 251–255

  61. 61

    Schurch B et al. (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164: 692–697

  62. 62

    Reitz A et al. (2004) European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45: 510–515

  63. 63

    Apostolidis A et al. (2005) Decreased sensory receptors P2x3 and TRPV1 in suburothealial nerve fibres following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 174: 977–983

  64. 64

    Popat R et al. (2005) A comparison between the response of patients with idiopathic detrusor overactivity (IDO) and neurogenic detrusor overactivity (NDO) to the first intradetrusor injection of botulinum A toxin. J Urol 174: 984–988

  65. 65

    Harper M et al. (2003) A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 92: 325–326

  66. 66

    Kalsi V et al. (2005) A cost consequence model for botulinum toxin-a used in the treatment of 89 patients with detrusor overactivity: preliminary results. Eur Urol 4: 104

  67. 67

    Chancellor MB and Blaivas JG (1993) Multiple Sclerosis. Probl Urol 7: 15–33

  68. 68

    Goldwasser B and Webster GD (1986) Augmentation and substitution enterocystoplasty. J Urol 135: 215–224

  69. 69

    Luangkhot R et al. (1991) Ileocecocystoplasty for the management of refractory neurogenic bladder: surgical technique and urodynamic findings. J Urol 146: 1340–1344

  70. 70

    Chartier-Kastler EJ et al. (2000) Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. J Urol 164: 1476–1480

  71. 71

    Barnes DG et al. (1993) Management of the neuropathic bladder by suprapubic catheterisation. Br J Urol 72: 169–172

Download references

Author information

Affiliations

  1. National Hospital for Neurology and Neurosurgery, Queen Square, London, UK

    • Vinay Kalsi
    •  & Clare J Fowler
  2. Institute of Neurology, London, UK

    • Vinay Kalsi
    •  & Clare J Fowler

Authors

  1. Search for Vinay Kalsi in:

  2. Search for Clare J Fowler in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Clare J Fowler.

About this article

Publication history

Received

Accepted

Issue Date

DOI

https://doi.org/10.1038/ncpuro0323

Further reading